September 2, 2018 to September 4, 2018

Eric Vivier, Chief Scientific Officer of Innate Pharma to participate in 3 sessions at upcoming ECI 2018:

  • Late Breaking Hot Topic 1

Sunday, September 2, 2018; 15:15-15:30; Room: Elicium

Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells

E. Vivier, P. André, Marseille, France


  • Symposia Track B - Tumor immunology and therapy

Symposium 3 - Tumor vaccination principles and immuno therapy

Monday, September 3, 2018; 08:30-09:45; Room: Elicium

Definition of Natural Killer cell heterogeneity in humans and mice by high-throughput single-cell RNA sequencing

Eric Vivier, France


  • Educational Session EDU.02 - The Utility of Theories in Immunology

Monday, September 3, 2018; 10:15-11:30; Room: Forum

The Discontinuity Theory of Immunity

Eric Vivier, France & Thomas Pradeu, France


Link to the ECI 2018 website.